Xu Wei, Xu Jinjin, Wang Ting, Liu Weibo, Wei Haifeng, Yang Xinghai, Yan Wangjun, Zhou Wang, Xiao Jianru
Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China.
Shanghai Key Laboratory of Regulatory Biology, Shanghai Key Laboratory of Brain Functional Genomics (Ministry of Education), Institute of Biomedical Sciences, East China Normal University, Shanghai 200241, P.R. China.
Oncol Lett. 2018 Jul;16(1):898-904. doi: 10.3892/ol.2018.8712. Epub 2018 May 16.
Osteosarcoma is a mesenchymally derived, high-grade bone sarcoma that is the most frequently diagnosed primary malignant bone tumor. Today, chemoprevention is regarded as a promising and realistic approach in the prevention of human cancer. Previous studies have suggested ellagic acid (EA) and Sennoside B have potential in this regard. The aim of the present study was to elucidate the anti-osteosarcoma effects of EA and Sennoside B by using Saos-2 and MG63 osteosarcoma cells. It was identified that EA or Sennoside B treatment could inhibit the growth, migration and invasion of the cells, and induce G cell cycle arrest by repressing the transcription of c-Jun. These results may provide a cellular basis for the application of EA or Sennoside B in the treatment of patients with osteosarcoma.
骨肉瘤是一种间充质来源的高级别骨肉瘤,是最常被诊断出的原发性恶性骨肿瘤。如今,化学预防被视为预防人类癌症的一种有前景且切实可行的方法。先前的研究表明,鞣花酸(EA)和番泻苷B在这方面具有潜力。本研究的目的是通过使用Saos-2和MG63骨肉瘤细胞来阐明EA和番泻苷B的抗骨肉瘤作用。研究发现,EA或番泻苷B处理可抑制细胞的生长、迁移和侵袭,并通过抑制c-Jun的转录诱导G期细胞周期停滞。这些结果可能为EA或番泻苷B在骨肉瘤患者治疗中的应用提供细胞基础。